Novartis (NVS) Gains 1.25% as Rhapsido® Data Presentation Approaches

Novartis AG Stock Performance on February 23, 2026

On February 23, 2026, Novartis AG (ticker symbol: NVS) showed a notable performance in the U.S. stock market. The stock opened at $163.66, traded within a range of $163.66 to $165.64, and closed at $164.70. This closing price marks an increase of $2.03, or 1.25%, compared to the previous close of $162.67. The trading volume for the day was approximately 1.96 million shares, contributing to a market capitalization near $314.27 billion.

Intraday Price Movements

Throughout the trading day, Novartis's stock price fluctuated between a low of $163.66 and a high of $165.64. The overall trading activity was robust, with a total value traded estimated at $314.27 million. The 1.25% price increase reflects strong investor interest, likely stimulated by the company’s recent announcements and clinical developments.

Corporate Announcements and News

1. Presentation of Rhapsido® Data: Novartis announced that it will present important data on its investigational drug Rhapsido® (remibrutinib) at the upcoming American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, scheduled from February 27 to March 2, 2026. The presentation will include findings from five major studies focusing on Rhapsido’s efficacy in treating chronic spontaneous urticaria (CSU) and its potential application in peanut allergies.
2. Clinical Trial Insights: The company highlighted new analyses from Phase III trials (REMIX-1 and REMIX-2) demonstrating Rhapsido’s effects on disease control and early symptom relief for CSU. Additional data from a Phase II trial assessing safety and efficacy in IgE-mediated peanut allergy will also be presented, which could impact market perceptions of the drug’s potential.
3. Regulatory Updates: Novartis is undergoing regulatory reviews for Rhapsido in several regions, including the European Union and Japan. Recent submissions to the FDA for treatment of symptomatic dermographism in chronic inducible urticaria (CIndU) were noted, indicating ongoing efforts to broaden the drug’s approved uses.
4. Future Development Plans: The company plans to initiate a Phase III program targeting food allergies in the second half of 2026. Positive topline results from the RemIND trial further enhance optimism around Rhapsido’s future prospects.
5. Divestiture of Indian Unit: Separately, Novartis announced its intention to divest its stake in Novartis India Limited for $159 million. This strategic move aims to streamline operations and focus on core growth areas. The announcement likely contributed to positive market sentiment.
6. Market Context: On the same day, the broader pharmaceutical sector experienced a general uptick, possibly driven by favorable sentiment towards healthcare and biotechnology. This environment may have supported Novartis’s stock performance.

Conclusion

Novartis AG’s stock performance on February 23, 2026, demonstrated a positive market response to key corporate developments, especially the upcoming presentation of Rhapsido® clinical data and ongoing regulatory initiatives. The 1.25% gain in share price signals investor confidence in Novartis’s strategic direction and product pipeline potential. The combination of clinical trial data, regulatory progress, and operational streamlining through divestiture contributed to a favorable market reaction, positioning Novartis strongly within the pharmaceutical industry landscape.